Surrozen, Inc. (NASDAQ:SRZN) Sees Large Increase in Short Interest

Surrozen, Inc. (NASDAQ:SRZN) was the target of a large increase in short interest during the month of April. As of April 15th, there was short interest totalling 36,200 shares, an increase of 358.2% from the March 31st total of 7,900 shares. Based on an average trading volume of 16,700 shares, the short-interest ratio is currently 2.2 days. Currently, 1.9% of the shares of the stock are sold short.

Insider Buying and Selling

In other Surrozen news, Director Tim Kutzkey acquired 193,548 shares of the business’s stock in a transaction on Thursday, April 4th. The stock was purchased at an average price of $15.50 per share, for a total transaction of $2,999,994.00. Following the transaction, the director now owns 332,885 shares in the company, valued at approximately $5,159,717.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 35.00% of the stock is owned by corporate insiders.

Institutional Trading of Surrozen

A hedge fund recently raised its stake in Surrozen stock. Euclidean Capital LLC increased its position in Surrozen, Inc. (NASDAQ:SRZN) by 63.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,315,463 shares of the company’s stock after purchasing an additional 512,500 shares during the quarter. Surrozen makes up 0.1% of Euclidean Capital LLC’s portfolio, making the stock its 12th biggest position. Euclidean Capital LLC owned 64.48% of Surrozen worth $645,000 at the end of the most recent reporting period. Institutional investors own 66.57% of the company’s stock.

Surrozen Stock Performance

SRZN traded up $0.37 during midday trading on Friday, hitting $8.98. The company had a trading volume of 11,126 shares, compared to its average volume of 27,275. Surrozen has a twelve month low of $4.50 and a twelve month high of $16.19. The company has a market capitalization of $28.73 million, a PE ratio of -0.52 and a beta of 0.74. The firm’s 50-day simple moving average is $12.07 and its 200-day simple moving average is $9.32.

About Surrozen

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. The company is developing antibody-based therapeutics with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.